Profile data is unavailable for this security.
About the company
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.
- Revenue in USD (TTM)4.70bn
- Net income in USD-4.15bn
- LocationIllumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
- Phone+1 (858) 202-4500
- Fax+1 (858) 202-4766
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|ILMN:NSQ since |
|IDbyDNA Inc||Deal completed||24 Jun 2022||24 Jun 2022Deal completed||10.58%||--|